Role of beta-arrestin 2 downstream of dopamine receptors in the basal ganglia

Frontiers in Neuroanatomy

Volumn , Issue SEP, 2011, Pages

  Del'Guidice, Thomas ^a   Lemasson, Morgane ^a   Beaulieu, Jean Martin ^a  

^a CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

Author keywords

Akt protein kinase B; Arrestin; Biased ligand pharmacology; Dopamine; G protein coupled receptors; Glycogen synthase kinase; MAP kinase; Striatum

Indexed keywords

ARIPIPRAZOLE; BETA ARRESTIN 2; BETA CATENIN; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; GLUTAMATE RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; HALOPERIDOL; LITHIUM; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

BASAL GANGLION; BINDING AFFINITY; BINDING SITE; BIPOLAR DISORDER; BRAIN REGION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVATION; IN VIVO STUDY; INTERNALIZATION; MOLECULAR CLOCK; MOLECULAR INTERACTION; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84862984712     PISSN: 16625129     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnana.2011.00058     Document Type: Review

References (116)

1. Ahn, S., Shenoy, S. K., Wei, H., and Lefkowitz, R. J. (2004). Differential kinetic and spatial patterns of betaarrestin and G protein-mediated ERK activation by the angiotensin II receptor. J. Biol. Chem. 279, 35518-35525.
2. Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., and Hemmings, B. A. (1996). Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15, 6541-6551.
3. Alimohamad, H., Rajakumar, N., Seah, Y. H., and Rushlow, W. (2005). Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol. Psychiatry 57, 533-542.
4. Altar, C. A., Hunt, R. A., Jurata, L. W., Webster, M. J., Derby, E., Gallagher, P., Lemire, A., Brockman, J., and Laeng, P. (2008). Insulin, IGF-1, and muscarinic agonists modulate schizophreniaassociated genes in human neuroblastoma cells. Biol. Psychiatry 64, 1077-1087.
5. Bannon, M. J., Wolf, M. E., and Roth, R. H. (1983). Pharmacology of dopamine neurons innervating the prefrontal, cingulate and piriform cortices. Eur. J. Pharmacol. 92, 119-125.
6. Beaulieu, J. M., and Caron, M. G. (2008). Looking at lithium: molecular moods and complex behaviour. Mol. Interv. 8, 230-241.
7. Beaulieu, J. M., and Gainetdinov, R. R. (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 63, 182-217.
8. Beaulieu, J. M., Gainetdinov, R. R., and Caron, M. G. (2007a). The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol. Sci. 28, 166-172.
9. Beaulieu, J. M., Tirotta, E., Sotnikova, T. D., Masri, B., Salahpour, A., Gainetdinov, R. R., Borrelli, E., and Caron, M. G. (2007b). Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J. Neurosci. 27, 881-885.
10. Beaulieu, J. M., Gainetdinov, R. R., and Caron, M. G. (2009). Akt/GSK3 signaling in the action of psychotropic drugs. Annu. Rev. Pharmacol. Toxicol. 49, 327-347.
11. Beaulieu, J. M., Marion, S., Rodriguiz, R. M., Medvedev, I. O., Sotnikova, T. D., Ghisi, V., Wetsel, W. C., Lefkowitz, R. J., Gainetdinov, R. R., and Caron, M. G. (2008a). A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132, 125-136.
12. Beaulieu, J. M., Zhang, X., Rodriguiz, R. M., Sotnikova, T. D., Cools, M. J., Wetsel, W. C., Gainetdinov, R. R., and Caron, M. G. (2008b). Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc. Natl. Acad. Sci. U.S.A. 105, 1333-1338.
13. Beaulieu, J. M., Sotnikova, T. D., Gainetdinov, R. R., and Caron, M. G. (2006). Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. J. Biol. Chem. 281, 32072-32080.
14. Beaulieu, J. M., Sotnikova, T. D., Marion, S., Lefkowitz, R. J., Gainetdinov, R. R., and Caron, M. G. (2005). An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122, 261-273.
15. Beaulieu, J. M., Sotnikova, T. D., Yao, W. D., Kockeritz, L., Woodgett, J. R., Gainetdinov, R. R., and Caron, M. G. (2004). Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U.S.A. 101, 5099-5104.
16. Benedetti, F., Bernasconi, A., Lorenzi, C., Pontiggia, A., Serretti, A., Colombo, C., and Smeraldi, E. (2004). A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci. Lett. 355, 37-40.
17. Berhow, M. T., Hiroi, N., and Nestler, E. J. (1996). Regulation of ERK (extracellular signal regulated kinase), part of the neurotrophin signal transduction cascade, in the rat mesolimbic dopamine system by chronic exposure to morphine or cocaine. J. Neurosci. 16, 4707-4715
18. Bjorklund, A., and Stenevi, U. (1984). Intracerebral neural implants: neuronal replacement and reconstruction of damaged circuitries. Annu. Rev. Neurosci. 7, 279-308.
19. Blanco, C., Laje, G., Olfson, M., Marcus, S. C., and Pincus, H. A. (2002). Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am. J. Psychiatry 159, 1005-1010.
20. Bohn, L. M., Gainetdinov, R. R., Sotnikova, T. D., Medvedev, I. O., Lefkowitz, R. J., Dykstra, L. A., and Caron, M. G. (2003). Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J. Neurosci. 23, 10265-10273.
21. Bychkov, E., Ahmed, M. R., Dalby, K. N., and Gurevich, E. V. (2007). Dopamine depletion and subsequent treatment with l-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. J. Neurochem. 102, 699-711.
22. Cade, J. F. (1949). Lithium salts in the treatment of psychotic excitement. Med. J. Aust. 2, 349-352.
23. Carlsson, A. (2001). A paradigm shift in brain research. Science 294, 1021-1024.
24. Chalecka-Franaszek, E., and Chuang, D. M. (1999). Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl. Acad. Sci. U.S.A. 96, 8745-8750.
25. Chen, G., Huang, L. D., Jiang, Y. M., and Manji, H. K. (1999). The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 72, 1327-1330.
26. Chen, P., Gu, Z., Liu, W., and Yan, Z. (2007). Glycogen synthase kinase 3 regulates N -methyl-d-aspartate receptor channel trafficking and function in cortical neurons. Mol. Pharmacol. 72, 40-51.
27. Claing, A., and Laporte, S. A. (2005). Novel roles for arrestins in G protein-coupled receptor biology and drug discovery. Curr. Opin. Drug Discov. Devel. 8, 585-589.
28. Claing, A., Laporte, S. A., Caron, M. G., and Lefkowitz, R. J. (2002). Endocytosis of G protein-coupled receptors: roles of G proteincoupled receptor kinases and betaarrestin proteins. Prog. Neurobiol. 66, 61-79.
29. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789.
30. Doble, B. W., and Woodgett, J. R. (2003). GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell. Sci. 116(Pt 7), 1175-1186.
31. Doi, M., Yujnovsky, I., Hirayama, J., Malerba, M., Tirotta, E., Sassone-Corsi, P., and Borrelli, E. (2006). Impaired light masking in dopamine D2 receptor-null mice. Nat. Neurosci. 9, 732-734.
32. Emamian, E. S., Hall, D., Birnbaum, M. J., Karayiorgou, M., and Gogos, J. A. (2004). Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 36, 131-137.
33. Ferguson, S. S. (2001). Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. 53, 1-24.
34. Ferguson, S. S., Downey, W. E. III, Colapietro, A. M., Barak, L. S., Ménard, L., and Caron, M. G. (1996). Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 271, 363-366.
35. Frame, S., and Cohen, P. (2001). GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359(Pt 1), 1-16.
36. Freyberg, Z., Ferrando, S. J., and Javitch, J. A. (2010). Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am. J. Psychiatry 167, 388-396.
37. Fukumoto, S., Hsieh, C. M., Maemura, K., Layne, M. D., Yet, S. F., Lee, K. H., Matsui, T., Rosenzweig, A., Taylor, W. G., Rubin, J. S., Perrella, M. A., and Lee, M. E. (2001). Akt participation in the Wnt signaling pathway through Dishevelled. J. Biol. Chem. 276, 17479-17483.
38. Gainetdinov, R. R., Bohn, L. M., Sotnikova, T. D., Cyr, M., Laakso, A., Macrae, A. D., Torres, G. E., Kim, K. M., Lefkowitz, R. J., Caron, M. G., and Premont, R. T. (2003). Dopaminergic supersensitivity in G protein-coupled receptor kinase 6deficient mice. Neuron 38, 291-303.
39. Gainetdinov, R. R., Premont, R. T., Bohn, L. M., Lefkowitz, R. J., and Caron, M. G. (2004). Desensitization of G protein-coupled receptors and neuronal functions. Annu. Rev. Neurosci. 27, 107-144.
40. Gainetdinov, R. R., Wetsel, W. C., Jones, S. R., Levin, E. D., Jaber, M., and Caron, M. G. (1999). Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283, 397-401.
41. Galandrin, S., Oligny-Longpré, G., and Bouvier, M. (2007). The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol. Sci. 28, 423-430.
42. Gerfen, C. R., and Surmeier, D. J. (2011). Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci. 34, 441-466.
43. Gesty-Palmer, D., Chen, M., Reiter, E., Ahn, S., Nelson, C. D., Wang, S., Eckhardt, A. E., Cowan, C. L., Spurney, R. F., Luttrell, L. M., and Lefkowitz, R. J. (2006). Distinct beta-arrestinand G protein-dependent pathways for parathyroid hormone receptorstimulated ERK1/2 activation. J. Biol. Chem. 281, 10856-10864.
44. Girault, J. A., Valjent, E., Caboch, J., and Hervé, D. (2007). ERK2: a logical AND gate critical for drug-induced plasticity? Curr. Opin. Pharmacol. 7, 77-85.
45. Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., and Caron, M. G. (1996). Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612.
46. Gould, T. D., K. C. O'Donnell, Picchini, A. M., Dow, E. R., Chen, G., and Manji, H. K. (2008). Generation and behavioral characterization of beta-catenin forebrainspecific conditional knock-out mice. Behav. Brain Res. 189, 117-125.
47. Gould, T. D., and Manji, H. K. (2005). Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30, 1223-1237.
48. Iitaka, C., Miyazaki, K., Akaike, T., and Ishida, N. (2005). A role for glycogen synthase kinase-3beta in the mammalian circadian clock. J. Biol. Chem. 280, 29397-29402.
49. Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., and Su, B. (2006). SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127, 125-137.
50. Jones, S. R., Gainetdinov, R. R., Wightman, R. M., and Caron, M. G. (1998). Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18, 1979-1986.
51. Kapur, S., and Remington, G. (2001). Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med. 52, 503-517.
52. Kebabian, J. W., and Calne, D. B. (1979). Multiple receptors for dopamine. Nature 277, 93-96.
53. Kim, K. M., Valenzano, K. J., Robinson, S. R., Yao, W. D., Barak, L. S., and Caron, M. G. (2001). Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins. J. Biol. Chem. 276, 37409-37414.
54. Kravitz, A. V., Freeze, B. S., Parker, P. R., Kay, K., Thwin, M. T., Deisseroth, K., and Kreitzer, A. C. (2010). Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 466, 622-626.
55. Krupnick, J. G., Goodman, O. B. Jr., Keen, J. H., and Benovic, J. L. (1997). Arrestin/clathrin interaction. Localization of the clathrin binding domain of nonvisual arrestins to the carboxy terminus. J. Biol. Chem. 272, 15011-15016.
56. Kuschinsky, K., and Hornykiewicz, O. (1974). Effects of morphine on striatal dopamine metabolism: possible mechanism of its opposite effect on locomotor activity in rats and mice. Eur. J. Pharmacol. 26, 41-50.
57. Lamont, E. W., Legault-Coutu, D., Cermakian, N., and Boivin, D. B. (2007). The role of circadian clock genes in mental disorders. Dialogues Clin. Neurosci. 9, 333-342.
58. Lan, H., Teeter, M. M., Gurevich, V. V., and Neve, K. A. (2009). An intracellular loop 2 amino acid residue determines differential binding of arrestin to the dopamine D2 and D3 receptors. Mol. Pharmacol. 75, 19-26.
59. Laporte, S. A., Miller, W. E., Kim, K. M., and Caron, M. G. (2002). beta-Arrestin/AP-2 interaction in G protein-coupled receptor internalization: identification of a beta-arrestin binging site in beta 2-adaptin. J. Biol. Chem. 277, 9247-9254.
60. Li, X., Bijur, G. N., and Jope, R. S. (2002). Glycogen synthase kinase3beta, mood stabilizers, and neuroprotection. Bipolar Disord. 4, 137-144.
61. Li, X., Rosborough, K. M., Friedman, A. B., Zhu, W., and Roth, K. A. (2007). Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int. J. Neuropsychopharmacol. 10, 7-19.
62. Li, X., Zhu, W., Roh, M. S., Friedman, A. B., Rosborough, K., and Jope, R. S. (2004). In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 29, 1426-1431.
63. Li, Y. C., Xi, D., Roman, J., Huang, Y. Q., and Gao, W. J. (2009). Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex. J. Neurosci. 29, 15551-15563.
64. Lohse, M. J., Benovic, J. L., Caron, M. G., and Lefkowitz, R. J. (1990a). Multiple pathways of rapid beta 2-adrenergic receptor desensitization. Delineation with specific inhibitors. J. Biol. Chem. 265, 3202-3211.
65. Lohse, M. J., Benovic, J. L., Codina, J., Caron, M. G., and Lefkowitz, R. J. (1990b). beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Science 248, 1547-1550.
66. Luttrell, L. M., and Gesty-Palmer, D. (2010). Beyond desensitization: physiological relevance of arrestindependent signaling. Pharmacol. Rev. 62, 305-330.
67. Luttrell, L. M., Roudabush, F. L., Choy, E. W., Miller, W. E., Field, M. E., Pierce, K. L., and Lefkowitz, R. J. (2001). Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc. Natl. Acad. Sci. U.S.A. 98, 2449-2454.
68. Mansour, H. A., Wood, J., Chowdari, K. V., Dayal, M., Thase, M. E., Kupfer, D. J., Monk, T. H., Devlin, B., and Nimgaonkar, V. L. (2005). Circadian phase variation in bipolar I disorder. Chronobiol. Int. 22, 571-584.
69. Martelli, A. M., Evangelisti, C., Chiarini, F., and McCubrey, J. A. (2010). The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 1, 89-103.
70. Masri, B., Salahpour, A., Didriksen, M., Ghisi, V., Beaulieu, J. M., Gainetdinov, R. R., and Caron, M. G. (2008). Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc. Natl. Acad. Sci. U.S.A. 105, 13656-13661.
71. Meltzer, H. Y. (1991). The mechanism of action of novel antipsychotic drugs. Schizophr. Bull. 17, 263-287
72. Miller, C. A., and Marshall, J. F. (2005). Molecular substrates for retrieval and reconsolidation of cocaineassociated contextual memory. Neuron 47, 873-884.
73. Missale, C., Nash, S. R., Robinson, S. W., Jaber, M., and Caron, M. G. (1998). Dopamine receptors: from structure to function. Physiol. Rev. 78, 189-225.
74. Oakley, R. H., Laporte, S. A., Holt, J. A., Barak, L. S., and Caron, M. G. (2001). Molecular determinants underlying the formation of stable intracellular G proteincoupled receptor-beta-arrestin complexes after receptor endocytosis*. J. Biol. Chem. 276, 19452-19460.
75. O'Brien, W. T., Harper, A. D., Jové, F., Woodgett, J. R., Maretto, S., Piccolo, S., and Klein, P. S. (2004). Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24, 6791-6798.
76. O'Brien, W. T., and Klein, P. S. (2009). Validating GSK3 as an in vivo target of lithium action. Biochem. Soc. Trans. 37(Pt 5), 1133-1138.
77. Pan, J. Q., Lewis, M. C., Ketterman, J. K., Clore, E. L., Riley, M., Richards, K. R., Berry-Scott, E., Liu, X., Wagner, F. F., Holson, E. B., Neve, R. L., Biechele, T. L., Moon, R. T., Scolnick, E. M., Petryshen, T. L., and Haggarty, S. J. (2011). AKT kinase activity is required for lithium to modulate mood-related behaviors in mice. Neuropsychopharmacology 36, 1397-1411.
78. Parent, M. B., Habib, M. K., and Baker, G. B. (2000). Time-dependent changes in brain monoamine oxidase activity and in brain levels of monoamines and amino acids following acute administration of the antidepressant/antipanic drug phenelzine. Biochem. Pharmacol. 59, 1253-1263.
79. Peineau, S., Bradley, C., Taghibiglou, C., Doherty, A., Bortolotto, Z. A., Wang, Y. T., and Collingridge, G. L. (2008). The role of GSK-3 in synaptic plasticity. Br. J. Pharmacol. 153(Suppl. 1), S428-37.
80. Phiel, C. J., and Klein, P. S. (2001). Molecular targets of lithium action. Annu. Rev. Pharmacol. Toxicol. 41, 789-813.
81. Pierce, K. L., and Lefkowitz, R. J. (2001). Classical and new roles of betaarrestins in the regulation of G-protein-coupled receptors. Nat. Rev. Neurosci. 2, 727-733.
82. Pitcher, J. A., Hall, R. A., Daaka, Y., Zhang, J., Ferguson, S. S., Hester, S., Miller, S., Caron, M. G., Lefkowitz, R. J., and Barak, L. S. (1998). The G protein-coupled receptor kinase 2 is a microtubule-associated protein kinase that phosphorylates tubulin. J. Biol. Chem. 273, 12316-12324.
83. Premont, R. T. (2005). Once and future signaling: G protein-coupled receptor kinase control of neuronal sensitivity. Neuromolecular Med. 7, 129-147.
84. Premont, R. T., and Gainetdinov, R. R. (2007). Physiological roles of G protein-coupled receptor kinases and arrestins. Annu. Rev. Physiol. 69, 511-534.
85. Rajagopal, S., Rajagopal, K., and Lefkowitz, R. J. (2010). Teaching old receptors new tricks: biasing seventransmembrane receptors. Nat. Rev. Drug Discov. 9, 373-386.
86. Ramsey, A. J., Laakso, A., Cyr, M., Sotnikova, T. D., Salahpour, A., Medvedev, I. O., Dykstra, L. A., Gainetdinov, R. R., and Caron, M. G. (2008). Genetic NMDA receptor deficiency disrupts acute and chronic effects of cocaine but not amphetamine. Neuropsychopharmacology 33, 2701-2714.
87. Rashid, A. J., So, C. H., Kong, M. M., Furtak, T., El-Ghundi, M., Cheng, R., O'Dowd, B. F., and George, S. R. (2007). D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc. Natl. Acad. Sci. U.S.A. 104, 654-659.
88. Rossig, L., Badorff, C., Holzmann, Y., Zeiher, A. M., and Dimmeler, S. (2002). Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J. Biol. Chem. 277, 9684-9689.
89. Sahar, S., Zocchi, L., Kinoshita, C., Borrelli, E., and Sassone-Corsi, P. (2010). Regulation of BMAL1 protein stability and circadian function by GSK3beta-mediated phosphorylation. PLoS ONE 5, e8561. doi: 10.1371/journal.pone.0008561
90. Santini, E., Valjent, E., Usiello, A., Carta, M., Borgkvist, A., Girault, J. A., Hervé, D., Greengard, P., and Fisone, G. (2007). Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J. Neurosci. 27, 6995-7005
91. Scheid, M. P., and Woodgett, J. R. (2001). PKB/AKT: functional insights from genetic models. Nat. Rev. Mol. Cell Biol. 2, 760-768.
92. Schou, M., Juel-Nielsen, N., Stromgren, E., and Voldby, H. (1954). The treatment of manic psychoses by the administration of lithium salts. J. Neurol. Neurosurg. Psychiatr. 17, 250-260.
93. Shenoy, S. K., and Lefkowitz, R. J. (2005). Angiotensin II-stimulated signaling through G proteins and beta-arrestin. Sci. STKE 2005, cm14.
94. Shuen, J. A., Chen, M., Gloss, B., and Calakos, N. (2008). Drd1atdTomato BAC transgenic mice for simultaneous visualization of medium spiny neurons in the direct and indirect pathways of the basal ganglia. J. Neurosci. 28, 2681-2685.
95. Snyder, S. H. (1976). The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am. J. Psychiatry 133, 197-202.
96. Souza, B. R., Romano-Silva, M. A., and Tropepe, V. (2011). Dopamine D2 receptor activity modulates Akt signaling and alters GABAergic neuron development and motor behavior in zebrafish larvae. J. Neurosci. 31, 5512-5525.
97. Spano, P. F., Govoni, S., and Trabucchi, M. (1978). Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. Adv. Biochem. Psychopharmacol. 19, 155-165.
98. Stambolic, V., Ruel, L., and Woodgett, J. R. (1996). Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol. 6, 1664-1668.
99. Stambolic, V., and Woodgett, J. R. (1994). Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem. J. 303(Pt 3), 701-704.
100. Svenningsson, P., Nishi, A., Fisone, G., Girault, J. A., Nairn, A. C., and Greengard, P. (2004). DARPP-32: an integrator of neurotransmission. Annu. Rev. Pharmacol. Toxicol. 44, 269-296.
101. Swift, J. L., Godin, A. G., Doré, K., Freland, L., Bouchard, N., Nimmo, C., Sergeev, M., De Koninck, Y., Wiseman, P. W., and Beaulieu, J. M. (2011). Quantification of receptor tyrosine kinase transactivation through direct dimerization and surface density measurements in single cells. Proc. Natl. Acad. Sci. U.S.A. 108, 7016-7021.
102. Urs, N. M., Daigle, T. L., and Caron, M. G. (2011). A dopamine D1 receptor-dependent beta-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice. Neuropsychopharmacology 36, 551-558.
103. Valjent, E., Bertran-Gonzalez, J., Hervé, D., Fisone, G., and Girault, J. A. (2009). Looking BAC at striatal signaling: cell-specific analysis in new transgenic mice. Trends Neurosci. 32, 538-547.
104. Valjent, E., Corvol, J. C., Pages, C., Besson, M. J., Maldonado, R., and Caboche, J. (2000). Involvement of the extracellular signal-regulated kinase cascade for cocaine rewarding properties. J. Neurosci. 20, 8701-8709.
105. Valjent, E., Corvol, J. C., Trzaskos, J. M., Girault, J. A., and Hervé, D. (2006a). Role of the ERK pathway in psychostimulant-induced locomotor sensitization. BMC Neurosci. 7, 20. doi: 10.1186/1471-2202-7-20
106. Valjent, E., Corbille, A. G., Bertran-Gonzalez, J., Hervé, D., and Girault, J. A. (2006b). Inhibition of ERK pathway or protein synthesis during reexposure to drugs of abuse erases previously learned place preference. Proc. Natl. Acad. Sci. U.S.A. 103, 2932-2937.
107. Valjent, E., Herve, D., and Girault, J. A. (2005). Drugs of abuse, protein phosphatases, and ERK pathway. Med. Sci. (Paris) 21, 453-454.
108. Wei, H., Ahn, S., Barnes, W. G., and Lefkowitz, R. J. (2004). Stable interaction between beta-arrestin 2 and angiotensin type 1A receptor is required for beta-arrestin 2-mediated activation of extracellular signal-regulated kinases 1 and 2. J. Biol. Chem. 279, 48255-48261.
109. Wei, H., Ahn, S., Shenoy, S. K., Karnik, S. S., Hunyady, L., Luttrell, L. M., and Lefkowitz, R. J. (2003). Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl. Acad. Sci. U.S.A. 100, 10782-10787.
110. Woodgett, J. R. (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9, 2431-2438.
111. Woodgett, J. R. (2001). Judging a protein by more than its name: GSK-3. Sci. STKE 2001, re12.
112. Woodgett, J. R. (2003). Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders. Curr. Drug Targets Immune Endocr. Metabol. Disord. 3, 281-290.
113. Yamada, T., Katagiri, H., Asano, T., Tsuru, M., Inukai, K., Ono, H., Kodama, T., Kikuchi, M., and Oka, Y. (2002). Role of PDK1 in insulinsignaling pathway for glucose metabolism in 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metab. 282, E1385-E1394.
114. Yuan, Q., Lin, F., Zheng, X., and Sehgal, A. (2005). Serotonin modulates circadian entrainment in Drosophila. Neuron 47, 115-127.
115. Yujnovsky, I., Hirayama, J., Doi, M., Borrelli, E., and Sassone-Corsi, P. (2006). Signaling mediated by the dopamine D2 receptor potentiates circadian regulation by CLOCK:BMAL1. Proc. Natl. Acad. Sci. U.S.A. 103, 6386-6391.
116. Zhu, L. Q., Wang, S. H., Liu, D., Yin, Y. Y., Tian, Q., Wang, X. C., Wang, Q., Chen, J. G., and Wang, J. Z. (2007). Activation of glycogen synthase kinase-3 inhibits longterm potentiation with synapseassociated impairments. J. Neurosci. 27, 12211-12220.